Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,718 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival of patients with small cell lung carcinoma in Taiwan.
Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC, Lai MS. Kuo YH, et al. Among authors: yang yy, yang jc. Oncology. 2012;82(1):19-24. doi: 10.1159/000335084. Epub 2012 Jan 20. Oncology. 2012. PMID: 22269348 Free article.
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. Johnson BE, et al. Among authors: yang jc. J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101054 Clinical Trial.
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Paz-Ares L, et al. Among authors: yang jc. J Thorac Oncol. 2015 Dec;10(12):1745-53. doi: 10.1097/JTO.0000000000000693. J Thorac Oncol. 2015. PMID: 26743856 Free article. Clinical Trial.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Park K, et al. Among authors: yang jc. Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. Lancet Oncol. 2016. PMID: 27083334 Clinical Trial.
Safety of gefitinib in non-small cell lung cancer treatment.
Hsiue EH, Lee JH, Lin CC, Yang JC. Hsiue EH, et al. Among authors: yang jc. Expert Opin Drug Saf. 2016 Jul;15(7):993-1000. doi: 10.1080/14740338.2016.1192605. Epub 2016 Jun 7. Expert Opin Drug Saf. 2016. PMID: 27212579 Review.
1,718 results